Research Library › Incretin & Amylin
Orforglipron is a small-molecule, non-peptide oral GLP-1 receptor agonist; unlike semaglutide or liraglutide, it is not a peptide at all. It was discovered by Chugai Pharmaceutical in Japan as OWL833, licensed to Eli Lilly in 2018, and developed by Lilly as LY3502970. The FDA approved it on 1 April 2026 as Foundayo for chronic weight management, the first new molecular entity approved under the FDA’s National Priority Voucher pilot.
Key facts
| Type | Small-molecule, non-peptide oral GLP-1 receptor agonist (partial agonist) |
|---|---|
| Other names | OWL833, LY3502970; brand Foundayo |
| Developed by | Discovered by Chugai Pharmaceutical Co., Ltd. (Japan); licensed to and developed by Eli Lilly and Company from 2018 |
| First described | 2018 license announcement; receptor structure published in PNAS in 2020 |
| Designed target | GLP-1 receptor, at a binding pocket distinct from that of the natural peptide hormone |
| Regulatory status (Oct 2026) | FDA-approved as Foundayo (1 Apr 2026) for chronic weight management; a US application for type 2 diabetes was submitted in 2026 and not yet approved as of late Sept 2026 |
Who developed it
Orforglipron was discovered by Chugai Pharmaceutical, a Japanese company in the Roche group, under the code OWL833 [1, 2]. In September 2018 Chugai granted Eli Lilly worldwide rights to develop and commercialize the compound, which was then described as an oral non-peptide GLP-1 receptor agonist about to enter Phase 1 testing. The original research program was in type 2 diabetes [2].
Lilly carried the compound, coded LY3502970, through clinical development under the nonproprietary name orforglipron. Lilly scientists were co-authors, with Chugai researchers, of the 2020 structural study of the molecule, and Lilly is the sponsor of the approved product, Foundayo [1, 3, 4].
Structure and design
Most GLP-1 receptor agonists, including semaglutide, tirzepatide and liraglutide, are modified peptides based on gut hormones. Orforglipron is instead a small organic molecule, designed so that it would not need to be built from amino acids. Lilly describes it as a small-molecule, non-peptide GLP-1 receptor agonist [1].
In 2020, scientists from Chugai, Lilly and Stanford University published a cryo-electron microscopy structure of the compound bound to the GLP-1 receptor [3]. They reported that it occupies a pocket in the upper part of the receptor formed by the extracellular domain, extracellular loop 2 and several transmembrane helices. In laboratory assays it behaved as a partial agonist that favored G-protein signaling over beta-arrestin recruitment [3]. These are in vitro structural and signaling findings.
Research history
- September 2018: Chugai licenses OWL833 to Lilly [2]
- November 2020: Receptor-bound structure of LY3502970 published in PNAS [3]
- 1 April 2026: FDA approves Foundayo for chronic weight management in adults [4]
- 2026: Lilly submits a US application for type 2 diabetes [5]
Regulatory status as of October 2026
The FDA approved orforglipron on 1 April 2026 as Foundayo, from Eli Lilly, for chronic weight management in adults with obesity, or with overweight plus at least one weight-related condition, alongside diet and physical activity [4]. It was the fifth approval and the first new molecular entity cleared under the Commissioner’s National Priority Voucher pilot, issued 50 days after filing and well ahead of the review goal date of 20 January 2027. The FDA described it as its fastest approval of a new molecular entity since 2002 [4].
Lilly reported in its second-quarter 2026 results that it had submitted orforglipron to the FDA for type 2 diabetes [5]. In a 29 September 2026 release, Lilly still described the compound as being studied for that use, and no approval for it had been announced [6]. Approvals outside the United States were not confirmed in the sources reviewed.
Because it is an approved drug, orforglipron sold outside the approved product is an unapproved drug under US law.
About this reference page
Kalibra Labs does not currently supply Orforglipron. This page is published as a neutral scientific and regulatory reference. Browse the Incretin & Amylin guide or the FDA Peptide Regulatory Tracker.
Frequently asked questions
Is orforglipron a peptide?
No. Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist, unlike peptide-based compounds such as semaglutide [1, 3].
How is orforglipron different from semaglutide?
Semaglutide is a modified peptide based on the GLP-1 hormone, while orforglipron is a small synthetic molecule that binds a different pocket of the same GLP-1 receptor [1, 3].
Who discovered orforglipron?
It was discovered by Chugai Pharmaceutical in Japan as OWL833 and licensed to Eli Lilly in 2018 [1, 2].
Is orforglipron FDA approved?
Yes. The FDA approved it on 1 April 2026 as Foundayo for chronic weight management in adults [4].
Sources
- Eli Lilly and Company. ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile. Press release, 16 Apr 2026. Link
- Chugai Pharmaceutical Co., Ltd. Chugai and Lilly enter into a license agreement for oral GLP-1 agonist, OWL833. Press release, 26 Sep 2018. Link
- Kawai T, Sun B, Yoshino H, et al., Kobilka BK, Sloop KW. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc Natl Acad Sci USA. 2020;117(47):29959–29967. doi:10.1073/pnas.2014879117. (PDB 6XOX) Link
- U.S. FDA. FDA approves first new molecular entity under National Priority Voucher program. Press announcement, 1 Apr 2026. Link
- Eli Lilly and Company. Lilly reports second-quarter 2026 financial results. Press release, 5 Aug 2026. Link
- Eli Lilly and Company. Release on Foundayo (orforglipron) indirect treatment comparison in type 2 diabetes. 29 Sep 2026. Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
Kalibra Labs does not supply this compound. This page is a scientific, historical and regulatory reference only; it is not medical advice and makes no claim about use in people or animals.
